Vaccine effectiveness varied across different age demographics and virus strains, offering the highest protection against influenza B and among children and adolescents during the 2024-2025 season, ...
A meta-analysis indicates HD-IIV is superior to SD-IIV for reducing hospitalizations in adults aged 65 years and older.
Children and adolescents who die from influenza-related illness are less likely to have received the vaccine for the current season, per an analysis of pediatric deaths over eight seasons in the US.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results